- Sotorasib (Lumakras) and adagrasib (Krazati)Sotorasib (Lumakras) and adagrasib (Krazati) are two new drugs that have been approved to treat people with non-small cell lung cancer that has the KRAS G12C mutation12345. Sotorasib was approved by the FDA in May 2021 as the first treatment for adult patients with non-small cell lung cancer harboring the KRASG12C genetic mutation who have received at least one prior systemic therapy25. Not all tumors with a KRAS G12C mutation respond to these drugs, however4.Learn more:✕This summary was generated using AI based on multiple online sources. To view the original source information, use the "Learn more" links.KRAS has been one of the most hard-to-hit targets in cancer research. But over the past 2 years, two new drugs, sotorasib (Lumakras) and adagrasib (Krazati), have been approved to treat people with non-small cell lung cancer that has the KRAS G12C mutation.www.cancer.gov/news-events/cancer-currents-blog…Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy.www.fda.gov/news-events/press-announcements/f…But finally, a drug called sotorasib (Lumakras™) — a drug similar to adagrasib — was proven effective for a subset of people with lung cancer found to have the KRAS -G12C mutation. The FDA approved sotorasib in May 2021.www.mskcc.org/news/advanced-colorectal-cancer …Last year, FDA approved the first KRAS inhibitor, sotorasib, to treat people with non-small cell lung cancer that has this specific KRAS mutation. Several other KRAS G12C inhibitors are being tested in late-stage clinical trials. Not all tumors with a KRAS G12C mutation respond to these drugs, however.www.cancer.gov/news-events/cancer-currents-blog…In May 2021, the United States Food and Drug Administration (FDA) approved sotorasib (Lumakras™) as the first treatment for adult patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C genetic mutation who have received at least one prior systemic therapy.jeccr.biomedcentral.com/articles/10.1186/s13046-0…
- People also ask
Targeting KRAS in cancer | Nature Medicine
WEBApr 18, 2024 · Recent data demonstrate that BI-2865 can inhibit many of the common KRAS mutations seen in cancer, including G12D, G12V, G12C and p.Gly13Asp (G13D), as well as wild-type KRAS, which is...
See results only from nature.comThe KRAS-G12C inhibitor: act…
The KRAS-G12C inhibitor: activity and resistance. Jiao Liu, Rui Kang & Daolin …
KRAS mutation: from undrug…
Excitingly, AMG510 was the first drug-targeting KRAS (G12C) to be approved …
WEBJun 25, 2021 · G12C is one of several KRAS mutations found in cancer cells. The two most common KRAS mutations are called G12D and G12V. KRAS normally acts like a light switch, toggling between being “on” and …
WEBJun 23, 2021 · In early-phase clinical trials, two potent, selective, and irreversible small-molecule KRAS G12C inhibitors have shown promising results in non–small-cell lung cancer (NSCLC) and more modest...
WEBMay 28, 2021. Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific...
WEBSep 20, 2020 · Sotorasib (AMG 510) is a small molecule that specifically and irreversibly inhibits KRAS G12C through a unique interaction with the P2 pocket (Fig. S1 in the Supplementary Appendix, available...
FDA grants accelerated approval to adagrasib for KRAS G12C …
WEBOn December 12, 2022, the Food and Drug Administration (FDA) granted accelerated approval to adagrasib (Krazati, Mirati Therapeutics, Inc.), a RAS GTPase family inhibitor, for adult patients with...
Adagrasib in Non–Small-Cell Lung Cancer Harboring a
WEBJun 3, 2022 · Adagrasib (MRTX849), a potent, orally available, small molecule covalent inhibitor of KRASG12C, irreversibly and selectively binds KRASG12C in its inactive, GDP-bound state. 9,15 Adagrasib...
KRAS G12C Mutations in NSCLC: From Target to Resistance
WEBMay 21, 2021 · A better understanding of the role of KRAS and its different mutations has led to the development of specific small-molecule inhibitors able to target KRAS G12C, an oncogenic driver mutation in a number of cancers, including non-small cell lung cancer.
- Some results have been removed
Skip to content
